Sequence Information

    • DRAMP ID

    • DRAMP29316

    • Name

    • Surotomycin(MK-4261/CB-183,315)

    • Sequence

    • Not available

    • Description

    • Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection. It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections. Surotomycin has a fourfold greater in vitro potency than vancomycin against C. Difficile and other Gram-positive bacteria with minimal impact on the Gram-negative organisms of the intestinal microbiota. Surotomycin, given orally, has been shown to be highly effective against both initial and relapsing hamster Clostridium difficile-associated diarrhea, with a potency similar to vancomycin. Surotomycin is non-inferior to vancomycin and offers a promising alternative for the treatment and prevention of C. diff infection.

    • Activity

    • Antibacterial

    • Target Organism

      • No MICs found on DRAMP database

    • Reference

      • Surotomycin (A Novel Cyclic Lipopeptide) vs. Vancomycin for the Treatment of Clostridioides difficile Infection: A Systematic Review and Meta-analysis.(PMID: 30924421)

Clinical Information

    • Medical use

    • Treatment of Diarrhea and Clostridium Difficile Infection

    • Company

    • Cubist Pharmaceuticals Inc./Merck & Co. Inc.

    • Stage of Development

    • Phase III

    • Comments

    • No more comments

    • Clinical Trials

    • NCT01598311
    • NCT01597505
    • NCT01085591
    • NCT02835105
    • NCT02835118